Trevi Therapeutics Confirms Phase 2b Trial Sample Size for Chronic Cough Treatment in IPF Patients Trevi Therapeutics announces that the sample size for its Phase 2b CORAL trial remains unchanged after a positive re-estimation result. Enrollment is at 75%.

Trevi Therapeutics Confirms Phase 2b Trial Sample Size for Chronic Cough Treatment in IPF Patients #United_States #New_Haven #Trevi_Therapeutics #Haduvio #IPF_Chronic_Cough